Presentations in the spotlight

Global Congress on Bladder Cancer 2019

Global Congress on Bladder Cancer 2019

  • Debate: the optimal therapy for a patient with high-risk NMIBC: RC vs intravesical therapy vs TMT
    Anthony Zietman
    Global Congress on Bladder Cancer 2019
    24 Oct 2019
  • Pathology and molecular data, where can we meet?
    Eva Comperat
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • PD-L1 testing: when and how
    Thomas Gevaert
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Immunotherapy: the patient's point of view
    Thomas Powles
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Case discussion on advanced urothelial cancer
    Ignacio Durán
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • New treatment options beyond immunotherapy
    Yohann Loriot
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • A practical guide to biomarkers
    Petros Grivas
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Combination therapy: ready for primetime?
    Ignacio Durán
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • SIOG update: treating elderly patients with bladder cancer
    Nicolas Mottet
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Debate: the optimal therapy for a patient with high-risk NMIBC: RC vs intravesical therapy vs TMT
    Kilian M. Gust
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Debate: the optimal therapy for a patient with high-risk NMIBC: RC vs intravesical therapy vs TMT
    Jacques Irani
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Debate: the optimal therapy for a patient with high-risk NMIBC: RC vs intravesical therapy vs TMT
    Anthony Zietman
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • New therapies for BCG unresponsive NMIBC: where do we stand?
    Ashish Kamat
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Case discussion on management of NMIBC in 2019
    Kilian M. Gust, Ashish Kamat, Jeroen van Moorselaar
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Diagnostic imaging for haematuria and bladder cancer: a fresh perspective challenging the status quo
    Nigel Cowan
    Global Congress on Bladder Cancer 2019
    25 Oct 2019
  • Treatment of advanced UTUC
    Maria De Santis
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Management of bladder and upper urinary tract urothelial carcinoma with targeted Copy Number Variations Profiling
    Eva Comperat
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Frozen section during radical cystectomy: is it still relevant?
    Jacques Irani
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Bladder preservation in MIBC: give me some oxygen
    Peter Hoskin
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Immunotherapy for MIBC: the future is now
    Andrea Necchi
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Case-based discussion on management of MIBC
    Ananya Choudhury
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Surgery-related complications and how to prevent them
    Kilian M. Gust
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Optimal trimodality treatment: what does it look like?
    Valérie Fonteyne
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Germline mutations: which patients need genetic testing today?
    Ignacio Durán
    Global Congress on Bladder Cancer 2019
    26 Oct 2019
  • Best poster session
    Global Congress on Bladder Cancer 2019
    26 Oct 2019

We are sorry, but your browser is out of date.

An additional plug-in or an upgrade of your browser is required to play this video.